4
↑0
↓4
—0
Evidence suggests Psilocybin maydecreaseAnxiety.
4 studies (4 claims)
Typical dose 4.4 mg
Exact normalized-entity scope. Exact scope. Claims must match the selected normalized intervention and endpoint IDs; signal links are not expanded. Direction describes the stored endpoint phrase and is not a benefit/harm judgement.
4 of 4
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psilocybin | Decreases - highly promising preliminary data have been produced | anxiety | Human | — | Not specified | Psychedelic drugs-a new era in psychiatry? .cited 53× |
| psilocybin | Decreases - reduction | anxiety | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.cited 59× |
| psilocybin | Decreases - showed a significant improvement | anxiety | Animal | SAPAP3 KO mice | 4.4 mg/kg, single intraperitoneal injection. | Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming.cited 6× |
| psilocybin | Decreases - supports its efficacy | anxiety | Human | — | Not specified | The Emergence of Psilocybin in Psychiatry and Neuroscience. |